Provided herein are synthetic peptides and methods for treating cardiorespiratory diseases, particularly cardiopulmonary disorder (CPD) by use of the synthetic peptides. The present synthetic peptide has the amino acid sequence of X.sub.1EX.sub.2LRVANEVTLN (SEQ ID NO: 1), in which X.sub.1 is tyrosine (Y) or phenylalanine (F), and X.sub.2 is alanine (A) or cysteine (C). In preferred embodiments, an effective amount of the present synthetic peptide is administered to a subject suffering from CPD to ameliorate or alleviate symptoms associated therewith.

The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways for a synergistic effect or highly selective effect.

The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways for a synergistic effect or highly selective effect.

The present disclosure describes a method of treating pulmonary disorders, such as pulmonary arterial hypertension, using a combination of a PDGF receptor kinase inhibitor and a prostanoid. The therapeutic formulations of the disclosure can inhibit cell growth and proliferation and target the underlying pathology of PAH.

The present disclosure describes a method of treating pulmonary disorders, such as pulmonary arterial hypertension, using a combination of a PDGF receptor kinase inhibitor and a prostanoid. The therapeutic formulations of the disclosure can inhibit cell growth and proliferation and target the underlying pathology of PAH.

The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.

The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.

The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.

The present invention herein discloses potent synergistic compositions of vasoactive mediators enhancers for improving vascular endothelial function. Particularly, the invention relates to synergistic nutritional composition comprising exogenous blend of N.sup.1-methyl nicotinamide chloride and standardized red spinach extract enriched with nitrate content along with pharmaceutically acceptable excipients, wherein N.sup.1-methyl nicotinamide salt and standardized red spinach extract enriched with nitrate content are present in the ratio of 1:0.5 to 1:8; and N.sup.1-methyl nicotinamide chloride and nitrate of standardized red spinach extract, are present in the ratio of 1:0.1 to 1:1. The present synergistic composition is useful for treating endothelial dysfunction such as hypertension, atherosclerosis, thrombosis, myocardial infarction, heart injury.

The present invention herein discloses potent synergistic compositions of vasoactive mediators enhancers for improving vascular endothelial function. Particularly, the invention relates to synergistic nutritional composition comprising exogenous blend of N.sup.1-methyl nicotinamide chloride and standardized red spinach extract enriched with nitrate content along with pharmaceutically acceptable excipients, wherein N.sup.1-methyl nicotinamide salt and standardized red spinach extract enriched with nitrate content are present in the ratio of 1:0.5 to 1:8; and N.sup.1-methyl nicotinamide chloride and nitrate of standardized red spinach extract, are present in the ratio of 1:0.1 to 1:1. The present synergistic composition is useful for treating endothelial dysfunction such as hypertension, atherosclerosis, thrombosis, myocardial infarction, heart injury.